Syndax Pharmaceuticals (SNDX) Research & Development (2015 - 2026)

Syndax Pharmaceuticals' Research & Development history runs 12 years deep, the most recent figure standing at $58.8 million for Q1 2026.

• On a quarterly basis, Research & Development fell 4.53% year-over-year to $58.8 million in Q1 2026; TTM through Mar 2026 was $256.0 million, a 34.15% increase from a year earlier, with the FY2025 full-year figure at $258.8 million, up 7.09% from the prior year.
• Research & Development slipped to $58.8 million in Q1 2026 per SNDX's latest filing, from $78.6 million in the prior quarter.
• Across five years, Research & Development topped out at $78.6 million in Q4 2025 and bottomed at $15.0 million in Q3 2024.
• The 5-year median for Research & Development is $48.7 million (2024), against an average of $45.4 million.
• Across the five-year window, Research & Development tumbled 61.62% in 2024 and soared 275.2% in 2025, its largest moves.
• Year by year, Research & Development stood at $31.8 million in 2022, then surged by 73.13% to $55.1 million in 2023, then grew by 18.87% to $65.5 million in 2024, then gained by 20.01% to $78.6 million in 2025, then dropped by 25.17% to $58.8 million in 2026.
• Per Business Quant, the three latest SNDX Research & Development figures stand at $58.8 million (Q1 2026), $78.6 million (Q4 2025), and $56.3 million (Q3 2025).